Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 122, Issue -, Pages 339-351Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2016.06.010
Keywords
PI3 kinase; Kinase selectivity; Platelet aggregation inhibitors; Thrombosis
Categories
Funding
- National Health and Medical Research Council of Australia (NHMRC) [1093062, 545943]
- National Health and Medical Research Council of Australia [1093062] Funding Source: NHMRC
Ask authors/readers for more resources
A series of amino-substituted triazines were developed and examined for PI3K13 inhibition and anti platelet function. Structural adaptations of a morpholine ring of the prototype pan-PI3K inhibitor ZSTK474 yielded PI3K beta selective compounds, where the selectivity largely derives from an interaction with the non-conserved Asp862 residue, as shown by site directed mutagenesis. The most PI3K beta selective inhibitor from the series was studied in detail through a series of in vitro and in vivo functional studies. MIPS-9922, 10 potently inhibited ADP-induced washed platelet aggregation. It also inhibited integrin alpha(IIb)beta(3) activation and alpha(IIb)beta(3) dependent platelet adhesion to immobilized vWF under high shear. It prevented arterial thrombus formation in the in vivo electrolytic mouse model of thrombosis without inducing prolonged bleeding or excess blood loss. (C) 2016 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available